Form 4: Voyager CMO Plans Sale of 19,000 Shares

Voyager Therapeutics' Chief Medical Officer, Toby Ferguson, reported a planned sale of 19,000 shares of common stock under a 10b5-1 plan.

Summary

• Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported a planned sale of common stock.
• The transaction, scheduled for August 18, 2025, involves 19,000 shares of common stock.
• The shares are expected to be sold at a weighted average price of $3.73 per share, with prices ranging from $3.69 to $3.79.
• Following this planned sale, Toby Ferguson will beneficially own 138,914 shares of Voyager Therapeutics common stock.
• The transaction is being conducted pursuant to a Rule 10b5-1 pre-planned trading arrangement.

Sentiment

Score: 4

Explanation: The planned sale of shares by a Chief Medical Officer, even under a pre-planned 10b5-1 arrangement, can be perceived as a slight reduction in insider alignment, though the pre-planned nature mitigates significant negative sentiment.

Positives

• The sale is being conducted under a Rule 10b5-1 pre-planned trading arrangement, indicating a structured personal financial management decision rather than an immediate reaction to company-specific news.

Negatives

• The planned sale by a Chief Medical Officer represents a reduction in insider ownership, which can sometimes be perceived as a slight decrease in insider alignment with shareholder interests.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the planned insider sale as a minor reduction in management's direct equity stake, though the 10b5-1 plan suggests it is for personal financial planning rather than a reflection of company performance.

Key Dates

Keywords

Voyager Therapeutics, VYGR, insider trading, Form 4, stock sale, Toby Ferguson, Chief Medical Officer, 10b5-1 plan